|
1
|
Cooper N and Ghanima W: Immune
thrombocytopenia. N Engl J Med. 381:945–955. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Audia S, Mahévas M, Samson M, Godeau B and
Bonnotte B: Pathogenesis of immune thrombocytopenia. Autoimmun Rev.
16:620–632. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gafter-Gvili A: Current approaches for the
diagnosis and management of immune thrombocytopenia. Eur J Intern
Med. 108:18–24. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cooper N, Kruse A, Kruse C, Watson S,
Morgan M, Provan D, Ghanima W, Arnold DM, Tomiyama Y, Santoro C, et
al: Immune thrombocytopenia (ITP) World Impact Survey (I-WISh):
Impact of ITP on health-related quality of life. Am J Hematol.
96:199–207. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bussel J, Kulasekararaj A, Cooper N, Verma
A, Steidl U, Semple JW and Will B: Mechanisms and therapeutic
prospects of thrombopoietin receptor agonists. Semin Hematol.
56:262–278. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pulanić D, Bátorová A, Bodó I, Červinek L,
Ionita I, Lissitchkov T, Melikyan A and Podolak-Dawidziak M: Use of
thrombopoietin receptor agonists in adults with immune
thrombocytopenia: A systematic review and Central European expert
consensus. Ann Hematol. 102:715–727. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lassandro G, Palladino V, Vecchio GCD,
Palmieri VV, Corallo PC, Faienza MF and Giordano P: Thrombopoietin
receptor agonists in children with immune thrombocytopenia: A new
therapeutic era. Endocr Metab Immune Disord Drug Targets.
21:397–406. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gebetsberger J, Streif W and Dame C:
Update on the use of thrombopoietin-receptor agonists in
pediatrics. Hamostaseologie. 44:316–325. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lucchesi A, Lovrencic B, McDonald V,
Newland A, Morgan M, Eriksson D, Wilson K, Giordano G, Carli G,
Geldman E, et al: Treatment preferences towards
thrombopoietin-receptor agonists for immune thrombocytopenia and
experience of disease (TRAPeze): Italy cohort. Hematology.
28(2253069)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ and Welch VA*(eds): Cochrane handbook for
systematic reviews of interventions. Version 6.5. Cochrane,
Alberta, 2024. Available from: http://www.cochrane.org/handbook.
|
|
12
|
George JN, Woolf SH, Raskob GE, Wasser JS,
Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton
JG, et al: Idiopathic thrombocytopenic purpura: A practice
guideline developed by explicit methods for the American society of
hematology. Blood. 88:3–40. 1996.PubMed/NCBI
|
|
13
|
Sterne JAC, Savović J, Page MJ, Elbers RG,
Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge
SM, et al: RoB 2: A revised tool for assessing risk of bias in
randomised trials. BMJ. 366(l4898)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bussel JB, Cheng G, Saleh MN, Psaila B,
Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et
al: Eltrombopag for the treatment of chronic idiopathic
thrombocytopenic purpura. N Engl J Med. 357:2237–2247.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bussel JB, Provan D, Shamsi T, Cheng G,
Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer
B, et al: Effect of eltrombopag on platelet counts and bleeding
during treatment of chronic idiopathic thrombocytopenic purpura: A
randomised, double-blind, placebo-controlled trial. Lancet.
373:641–648. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cheng G, Saleh MN, Marcher C, Vasey S,
Mayer B, Aivado M, Arning M, Stone NL and Bussel JB: Eltrombopag
for management of chronic immune thrombocytopenia (RAISE): A
6-month, randomised, phase 3 study. Lancet. 377:393–402.
2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tomiyama Y, Miyakawa Y, Okamoto S,
Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S,
Ozaki K, et al: A lower starting dose of eltrombopag is efficacious
in Japanese patients with previously treated chronic immune
thrombocytopenia. J Thromb Haemost. 10:799–806. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Grainger JD, Locatelli F,
Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P,
Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, et al:
Eltrombopag for children with chronic immune thrombocytopenia
(PETIT2): A randomised, multicentre, placebo-controlled trial.
Lancet. 386:1649–1658. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang R, Li J, Jin J, Huang M, Yu Z, Xu X,
Zhang X and Hou M: Multicentre, randomised phase III study of the
efficacy and safety of eltrombopag in Chinese patients with chronic
immune thrombocytopenia. Br J Haematol. 176:101–110.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Huang YT, Liu XF, Chen YF, Fu RF, Liu W,
Zhang L and Yang RC: The efficacy and safety of eltrombopag in
Chinese patients with chronic immune thrombocytopenia. Zhonghua Xue
Ye Xue Za Zhi. 39:32–36. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
21
|
Arnold DM, Heddle NM, Cook RJ, Hsia C,
Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, et
al: Perioperative oral eltrombopag versus intravenous
immunoglobulin in patients with immune thrombocytopenia: A
non-inferiority, multicentre, randomised trial. Lancet Haematol.
7:e640–e648. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang
R, Qin J, Lv T, Qin F, Cai H, et al: A multicentre double-blind,
double-dummy, randomised study of recombinant human thrombopoietin
versus eltrombopag in the treatment of immune thrombocytopenia in
Chinese adult patients. Br J Haematol. 195:781–789. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bussel JB, Kuter DJ, Aledort LM, Kessler
CM, Cuker A, Pendergrass KB, Tang S and McIntosh J: A randomized
trial of avatrombopag, an investigational thrombopoietin-receptor
agonist, in persistent and chronic immune thrombocytopenia. Blood.
123:3887–3894. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jurczak W, Chojnowski K, Mayer J, Krawczyk
K, Jamieson BD, Tian W and Allen LF: Phase 3 randomised study of
avatrombopag, a novel thrombopoietin receptor agonist for the
treatment of chronic immune thrombocytopenia. Br J Haematol.
183:479–490. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G,
Cheng P, Huang R, Yang L, Hu J, et al: A multicenter, randomized
phase III trial of hetrombopag: A novel thrombopoietin receptor
agonist for the treatment of immune thrombocytopenia. J Hematol
Oncol. 14(37)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sun Q, Wang H, Chen L, Shao J, Zhang W,
Zhou F and Jian X: Effect analysis of recombinant human
thrombopoietin and herombopag on immune function in patients with
primary immune thrombocytopenia. Int J Blood Transfus Hematol.
47:503–511. 2024.
|
|
27
|
Wang X, Li Y and Zhuang W: Safety analysis
of romiplostim, eltrombopag, and avatrombopag post-market approval:
A pharmacovigilance study based on the FDA adverse event reporting
system. BMC Pharmacol Toxicol. 26(46)2025.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Deng Y, Madatian A, Wire MB, Bowen C, Park
JW, Williams D, Peng B, Schubert E, Gorycki F, Levy M and Gorycki
PD: Metabolism and disposition of eltrombopag, an oral, nonpeptide
thrombopoietin receptor agonist, in healthy human subjects. Drug
Metab Dispos. 39:1734–1746. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nomoto M, Pastino G, Rege B, Aluri J,
Ferry J and Han D: Pharmacokinetics, pharmacodynamics,
pharmacogenomics, safety, and tolerability of avatrombopag in
healthy Japanese and white subjects. Clin Pharmacol Drug Dev.
7:188–195. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Zheng L, Liang MZ, Zeng XL, Li CZ, Zhang
YF, Chen XY, Zhu X and Xiang AB: Safety, pharmacokinetics and
pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in
healthy individuals. Basic Clin Pharmacol Toxicol. 121:414–422.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li F, Lin H, Feng S, Cai L, Zhang L, Feng
S, Liu X, Chen Z, Zou Q, Wu Y, et al: A phase I, single-sequence,
open-label study to evaluate the drug-drug interaction between
hetrombopag and cyclosporine in healthy Chinese subjects. Br J Clin
Pharmacol. 89:2160–2167. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wong RSM, Saleh MN, Khelif A, Salama A,
Portella MSO, Burgess P and Bussel JB: Safety and efficacy of
long-term treatment of chronic/persistent ITP with eltrombopag:
Final results of the EXTEND study. Blood. 130:2527–2536.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Saleh MN, Bussel JB, Cheng G, Meyer O,
Bailey CK, Arning M and Brainsky A: EXTEND Study Group. Safety and
efficacy of eltrombopag for treatment of chronic immune
thrombocytopenia: Results of the long-term, open-label EXTEND
study. Blood. 121:537–545. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang P and Miao W: Eltrombopag-induced
liver dysfunction during the treatment of immune thrombocytopenia
and its risk factors. Ann Palliat Med. 10:6419–6424.
2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Despotovic JM and Grimes AB: Pediatric
ITP: Is it different from adult ITP? Hematology Am Soc Hematol Educ
Program. 2018:405–411. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Terrault N, Chen YC, Izumi N, Kayali Z,
Mitrut P, Tak WY, Allen LF and Hassanein T: Avatrombopag before
procedures reduces need for platelet transfusion in patients with
chronic liver disease and thrombocytopenia. Gastroenterology.
155:705–718. 2018.PubMed/NCBI View Article : Google Scholar
|
